Browsing by Author "Bove, V"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
    Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America
    (Lippincott Williams and Wilkins, 2022) Bove, V; Riva, E; Vásquez-Chavez, J; Peña, C; Seehaus, C; Samanez, C; Bustos, J; Hernández, M; Fernández, J; Ríos, O; Rodríguez, Y; Figueredo, I; Fantl, D; Malpica, L
    PURPOSE: Infections are a significant cause of morbidity and mortality in patients with multiple myeloma (MM). In Latin America, data on infectious complications in this patient population are lacking. METHODS: We conducted a prospective cohort study of patients with newly diagnosed MM (NDMM) in seven Latin American countries between June 2019 and May 2020. Patients with active disease, on active therapy, and with a follow-up of 6 months from the time of diagnosis were included. Our primary end point was the number of infectious events that required hospitalization for ≥ 24 hours. RESULTS: Of 248 patients with NDMM, 89 (35.9%) had infectious complications (113 infectious events), the majority (67.3%) within the first 3 months from diagnosis. The most common sites of infection were respiratory (38%) and urinary tract (31%). The microbial agent was identified in 57.5% of patients with gram-negative bacteria (73.5%) as the most common pathogen. Viral infections were infrequent, and no patients with fungal infection were reported. In the multivariable analysis, diabetes mellitus (odds ratio [OR], 2.71 95% CI, 1.23 to 6.00 P = .014), creatinine ≥ 2 mg/dL (OR, 4.87 95% CI, 2.29 to 10.35 P < .001), no use of trimethoprim-sulfamethoxazole prophylaxis (OR, 6.66 95% CI, 3.43 to 12.92 P < .001), and treatment with immunomodulatory drugs (OR, 3.02 95% CI, 1.24 to 6.29 P = .003) were independent factors associated with bacterial infections. At 6 months, 21 patients (8.5%) had died, 47.6% related to infectious complications. CONCLUSION: Bacterial infections are a substantial cause of hospital admissions and early death in patients with NDMM. Antibiotic prophylaxis should be considered to reduce infectious complications in patients with MM.
  • Thumbnail Image
    Publication
    Patients Age 40 Years and Younger with Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence from Latin America
    (Lippincott Williams and Wilkins, 2023) Martinez-Cordero, H; Peña, C; Schutz, NP; Bove, V; Villano, F; Beltran, C; Donoso, J; Lopez-Vidal, H; Roa-Salinas, MA; Soto, P; Ochoa, P; Duarte, P; Remaggi, G; Corzo, A; Shanley, C; Lopresti, S; Orlando, S; Verri, V; Quiroga, LD; Fantl, D; Ramirez, J; Ospina-Idarraga, A; Idrobo, H; Quintero, G; Gomez, R; Cantu-Martinez, O; Gomez-Almaguer, D; Ruiz-Arguelles, GJ; Galvez-Cardenas, KM; Salazar, LA; Novoa-Caicedo, I; Fuentes-Lacouture, MC; Spirko, P; Arbelaez, MI; Pereira, M; Valdes, J; Vasquez, J; Von-Glasenapp, A; Riva, E
    PURPOSEMultiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce.PATIENTS AND METHODSWe analyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MM age 40 years or younger compared with 256 patients age 41-50 years and 957 patients age 51 years or older.RESULTSThere were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Of the patients age 40 years or younger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival.CONCLUSIONIn conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly. © American Society of Clinical Oncology.
  • Thumbnail Image
    Publication
    Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group
    (Taylor and Francis Ltd., 2023) Peña, C; Riva, E; Schutz, N; Ramírez, A; Vásquez, J; del-Carpio, D; Seehaus, C; Ochoa, P; Vengoa, R; Duarte, P; Martínez-Cordero, H; Figueredo, Y; Ríos, RO; Ramírez, J; Bove, V; Roa, M; Russo, M; Espinoza, M; Rodriguez, G; Remaggi, G; Enciso, ME; Chandía, M; Fantl, D.
    Primary plasma cell leukemia (pPCL) is an infrequent and aggressive plasma cell disorder. The prognosis is still very poor, and the optimal treatment remains to be established. A retrospective, multicentric, international observational study was performed. Patients from 9 countries of Latin America (LATAM) with a diagnosis of pPCL between 2012 and 2020 were included. 72 patients were included. Treatment was based on thalidomide in 15%, proteasome inhibitors (PI)-based triplets in 38% and chemotherapy plus IMIDs and/or PI in 29%. The mortality rate at 3 months was 30%. The median overall survival (OS) was 18 months. In the multivariate analysis, frontline PI-based triplets, chemotherapy plus IMIDs and/or PI therapy, and maintenance were independent factors of better OS. In conclusion, the OS of pPCL is still poor in LATAM, with high early mortality. PI triplets, chemotherapy plus IMIDs, and/or PI and maintenance therapy were associated with improved survival. © 2023 Informa UK Limited, trading as Taylor & Francis Group.
  • Thumbnail Image
    Publication
    Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study
    (Lippincott Williams and Wilkins, 2022) Riva E; Duarte PJ; Valcárcel, B; Remaggi, G; Murrieta, I; Corzo, A; Del Carpio, D; Peña, C; Vásquez, J; Bove, V; Teixeira, L; Fleury-Perini, G; Yantorno, S; Samánez, C; Lopresti, S; Altamirano, M; Villela, L; Ruiz-Arguelles, GJ; Ruiz-Delgado, GJ; Montaño, E; Verri, V; Zamora-Pérez, E; Pérez-Jacobo, F; Idrobo, H; Martínez-Cordero, H; Beltran, BE; Ramírez, J; Castillo, JJ; Malpica-Castillo, LE
    PURPOSE: Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, and outcome patterns of WM in Latin America. METHODS: We retrospectively analyzed patients with WM diagnosed between 1991 and 2019 from 24 centers in seven Latin American countries. The study outcomes were overall survival (OS) and progression-free survival (PFS). RESULTS: We identified 159 cases (median age 67 years, male 62%). Most patients (95%) were symptomatic at diagnosis. The International Prognostic Scoring System for WM (IPSSWM) at diagnosis was available in 141 (89%) patients (high-risk 40%, intermediate-risk 37%, and low-risk 23%). Twenty-seven (17%) patients were tested for MYD88L265P, with 89% (n = 24 of 27) carrying the mutation. First-line and second-line therapies were administered to 142 (89%) and 53 (33%) patients, respectively. Chemoimmunotherapy was the most commonly used first-line (66%) and second-line (45%) approach